OCGN - Ocugen Inc. (OCGN) Investigation: Bronstein Gewirtz & Grossman LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN). Investors who purchased Ocugen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OCGN.

Investigation Details:

On April 1, 2024, Ocugen submitted a current report on Form 8-K to the SEC after the market closed. The report stated that the Audit Committee of the Board of Directors, in consultation with EY and upon the recommendation of management, concluded that the previously-issued audited consolidated financial statements for each fiscal year starting from January 1, 2020, as well as the previously-issued unaudited interim condensed consolidated financial statements for the first three quarters of those years, were significantly misstated. As a result, they should no longer be relied upon. This conclusion also applied to the associated earnings releases, investor presentations, and other communications that described those financial statements.

Additionally, on April 1, 2024, the company filed a notification on Form 12b-25, informing about its inability to file Form 10-K in a timely manner. The reason for this delay was the need for additional time to correct the aforementioned errors and prepare restated financial statements. The company anticipates filing the 2023 Form 10-K by April 16, 2024, but there is no guarantee that they will be able to meet this deadline.

What's Next?

If you are aware of any facts relating to this investigation or purchased Ocugen securities, you can assist this investigation by visiting the firm's site: bgandg.com/OCGN. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC